Abituzumab - Merck Serono

Drug Profile

Abituzumab - Merck Serono

Alternative Names: Anti-CD51 antigen mAb; Anti-integrin alphaV mAb; DI 17E6; EMD525797

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono; Merck Serono
  • Developer Merck Serono
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Integrin alphaV antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic scleroderma
  • Discontinued Colorectal cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 02 May 2018 Merck enters into a agreement with with SFJ Pharmaceuticals to develop abituzumab through a novel risk-sharing collaboration agreement
  • 11 Jan 2018 Merck and EMD Serono discontinues phase-II clinical trials in Systemic scleroderma in USA, Spain, United Kingdom, Poland, Italy, Israel, Canada, Australia, Argentina (IV) (NCT02745145)
  • 15 Apr 2016 Merck and EMD Serono Research & Development Institute plan a phase II trial for Systemic scleroderma (associated interstitial lung disease) in USA, Germany, France, Italy, Poland, Spain, United Kingdom, Argentina, Australia, Canada, Israel and Turkey (IV) (NCT02745145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top